131 related articles for article (PubMed ID: 26091673)
1. Progress in Prostate Cancer (at Last!).
Glodé LM
Oncology (Williston Park); 2015 Jun; 29(6):407, 414. PubMed ID: 26091673
[No Abstract] [Full Text] [Related]
2. Highlights from the 29th European Society for Medical Oncology Congress: Vienna, Austria, October 29 through November 2, 2004.
Price N
Clin Prostate Cancer; 2004 Dec; 3(3):136-40. PubMed ID: 15636678
[No Abstract] [Full Text] [Related]
3. ESMO 2014: new trends in precision medicine.
Morere JF; Innominato P
Target Oncol; 2014 Dec; 9(4):293-4. PubMed ID: 25503266
[No Abstract] [Full Text] [Related]
4. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.
Masters GA; Krilov L; Bailey HH; Brose MS; Burstein H; Diller LR; Dizon DS; Fine HA; Kalemkerian GP; Moasser M; Neuss MN; O'Day SJ; Odenike O; Ryan CJ; Schilsky RL; Schwartz GK; Venook AP; Wong SL; Patel JD
J Clin Oncol; 2015 Mar; 33(7):786-809. PubMed ID: 25605863
[No Abstract] [Full Text] [Related]
5. Experimental models for the development of new medical treatments in prostate cancer.
Chauchereau A
Eur J Cancer; 2011 Sep; 47 Suppl 3():S200-14. PubMed ID: 21943976
[No Abstract] [Full Text] [Related]
6. Chemotherapy of hormone refractory prostatic cancer.
Stoter G; Jones WG
Prog Clin Biol Res; 1988; 260():123-5. PubMed ID: 3129730
[No Abstract] [Full Text] [Related]
7. Systemic therapeutic strategies for prostate cancer.
Nelson WG
Clin Adv Hematol Oncol; 2005 Aug; 3(8):619-21. PubMed ID: 16167046
[No Abstract] [Full Text] [Related]
8. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.
Armstrong AJ
Oncology (Williston Park); 2014 Oct; 28(10):881, 883. PubMed ID: 25323615
[No Abstract] [Full Text] [Related]
9. [Hormone-refractory metastatic prostate carcinoma -- combination improves survival].
Aktuelle Urol; 2005 Sep; 36(5):385-7. PubMed ID: 16163602
[No Abstract] [Full Text] [Related]
10. Optimal timing of chemotherapy in androgen independent prostate cancer.
Schnadig ID; Beer TM
Urol Oncol; 2009; 27(1):97-100. PubMed ID: 19111808
[TBL] [Abstract][Full Text] [Related]
11. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis.
Suzman DL; Antonarakis ES
Oncology (Williston Park); 2014 Oct; 28(10):880, 882. PubMed ID: 25323614
[No Abstract] [Full Text] [Related]
12. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
13. Repurposing to fight cancer: the metformin-prostate cancer connection.
Azvolinsky A
J Natl Cancer Inst; 2014 Feb; 106(2):dju030. PubMed ID: 24511112
[No Abstract] [Full Text] [Related]
14. New drugs and treatment strategies in prostate cancer.
Galsky MD
Clin Adv Hematol Oncol; 2014 Jan; 12(1):51-3. PubMed ID: 25000316
[No Abstract] [Full Text] [Related]
15. Atrasentan demonstrates survival benefit in hormone-refractory prostate cancer.
Expert Rev Anticancer Ther; 2002 Jun; 2(3):245. PubMed ID: 12113043
[No Abstract] [Full Text] [Related]
16. Chemotherapy for advanced prostate cancer: 25 years later.
Logothetis CJ; Millikan R
J Clin Oncol; 2008 May; 26(15):2423-4. PubMed ID: 18487561
[No Abstract] [Full Text] [Related]
17. Cooperative clinical trials in prostate cancer.
Murphy GP; Slack NH
Prog Clin Biol Res; 1981; 75B():341-6. PubMed ID: 7323102
[No Abstract] [Full Text] [Related]
18. State-of-the-art prostate cancer treatment and research. A report from the Cancer Institute of New Jersey.
DiPaola RS; Kumar P; Hait WN; Weiss RE
N J Med; 2001 Feb; 98(2):23-33. PubMed ID: 11221439
[TBL] [Abstract][Full Text] [Related]
19. [Hormonal treatment of cancer of the prostate: review and present status].
Ganzer R; Wieland WF; Bach T; Rössler W; Blana A
Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333
[No Abstract] [Full Text] [Related]
20. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
de Voogt HJ; Pavone-Macaluso M; Smith PH; de Pauw M; Suciu S
Prog Clin Biol Res; 1988; 260():111-7. PubMed ID: 2966403
[No Abstract] [Full Text] [Related]
[Next] [New Search]
